Table 4

Treatment characteristics

CharacteristicCorticosteroidRituximab
Single-agent prednisoneAny corticosteroid-containing therapySingle-agent rituximabAny rituximab-containing therapyPurine analogAlkylating agentOther therapy*
No.%No.%No.%No.%No.%No.%No.%
Treatments 26  35  47  77  10  59  24  
Patients treated 24  30  32  44  8  37  21  
Used as first-line therapy 21 81 23 69 14 30 23 30 2 20 21 36 7 29 
Used as part of dual- or multi-modality therapy —  7 20 —  30 39 6 60 39 66 14 58 
Duration of therapy mo†               
 Treatments with available data 19  27  38  65  5  41  14  
 Median 3.0 1.9 1.0 1.0 4.0 3.2 2.8 
 Range 0.1-13.9 0.1-120.0 0.1-20.4 0.1-107.7 1.0-24.5 0.0-46.4 0.0-108.7 
Tolerated therapy 22 85 29 83 42 89 71 92 9 90 49 83 21 88 
Patients with known underlying hematologic disorder 18/24 75 24/30 80 31/32 97 38/44 86 7/8 88 31/37 84 17/21 81 
Lymphoproliferative disorder‡ 10  12  16  20  7  17  12  
Other hematologic disorder§ 8  12  15  18  0  14  5  
Concurrent need for transfusion|| 9 35 12 34 6 13 16 21 2 20 14 24 9 38 
 Decreased need after therapy 1 11 3 25 6 100 10 63 1 50 3 21 2 8 
 Increased need after therapy 0 0 0 0 0 0 0 0 0 0 1 7 3 13 
Confirmed response to therapy 9 36 14 42 39 83 61 79 5 63 26 46 11 48 
 Treatments with available data 25  33  47  77  8  57  23  
Duration of response, mo               
 Median 60.0 51.6 27.0 24.0 18.5 11.3 36.6 
 Range 2.9-210.8 7.0-210.8 2.0-135.6 1.0-135.6 12.0-41.7 0.4-146.8 1.0-166.5 
Further treatment required# 17 65 24 69 23 49 42 55 6 60 40 68 14 58 
CharacteristicCorticosteroidRituximab
Single-agent prednisoneAny corticosteroid-containing therapySingle-agent rituximabAny rituximab-containing therapyPurine analogAlkylating agentOther therapy*
No.%No.%No.%No.%No.%No.%No.%
Treatments 26  35  47  77  10  59  24  
Patients treated 24  30  32  44  8  37  21  
Used as first-line therapy 21 81 23 69 14 30 23 30 2 20 21 36 7 29 
Used as part of dual- or multi-modality therapy —  7 20 —  30 39 6 60 39 66 14 58 
Duration of therapy mo†               
 Treatments with available data 19  27  38  65  5  41  14  
 Median 3.0 1.9 1.0 1.0 4.0 3.2 2.8 
 Range 0.1-13.9 0.1-120.0 0.1-20.4 0.1-107.7 1.0-24.5 0.0-46.4 0.0-108.7 
Tolerated therapy 22 85 29 83 42 89 71 92 9 90 49 83 21 88 
Patients with known underlying hematologic disorder 18/24 75 24/30 80 31/32 97 38/44 86 7/8 88 31/37 84 17/21 81 
Lymphoproliferative disorder‡ 10  12  16  20  7  17  12  
Other hematologic disorder§ 8  12  15  18  0  14  5  
Concurrent need for transfusion|| 9 35 12 34 6 13 16 21 2 20 14 24 9 38 
 Decreased need after therapy 1 11 3 25 6 100 10 63 1 50 3 21 2 8 
 Increased need after therapy 0 0 0 0 0 0 0 0 0 0 1 7 3 13 
Confirmed response to therapy 9 36 14 42 39 83 61 79 5 63 26 46 11 48 
 Treatments with available data 25  33  47  77  8  57  23  
Duration of response, mo               
 Median 60.0 51.6 27.0 24.0 18.5 11.3 36.6 
 Range 2.9-210.8 7.0-210.8 2.0-135.6 1.0-135.6 12.0-41.7 0.4-146.8 1.0-166.5 
Further treatment required# 17 65 24 69 23 49 42 55 6 60 40 68 14 58 
*

Other therapy included azathioprine, erythropoietin, danazol, interferon alpha, plasma exchange, intravenous immunoglobulin, methotrexate, cyclosporine, or vincristine.

†

Patients with “0” duration received 1 infusion or treatment (1 day) without continuation of therapy.

‡

Includes chronic lymphocytic leukemia, macroglobulinemia, unspecified lymphoproliferative disorders, and other lymphomas. T-cell lymphoma was excluded.

§

Includes MGUS and T-cell lymphoma.

||

Transfusion requirement was noted for each individual round of therapy, not overall patient course, to reflect the effect of the unique therapeutic agent.

Response to therapy was noted for each round of therapy, not overall patient treatment course, to reflect the unique response to the specific therapeutic regimen.

#

Requirement for further treatment was noted for each round of therapy to reflect their individual efficacies.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal